Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
Rhythm Pharmaceuticals (NASDAQ:RYTM), a $6.5 billion market cap biotech company whose stock has surged 112% over the past year, reported that Chief Technical Officer Joseph Shulman sold 3,984 shares of common stock on August 11, 2025, at prices ranging from $90.00 to $90.27, for a total value of $358,891. The sale was executed under a Rule 10b5-1 trading plan adopted on August 8, 2024. According to InvestingPro analysis, the stock is currently trading near its 52-week high of $99.04, with technical indicators suggesting overbought conditions.
On the same day, Shulman also exercised options to acquire 3,984 shares of Rhythm Pharmaceuticals common stock at an exercise price of $6.8, for a total value of $27091. These options were granted on February 9, 2022, and vest in installments over a period of service.
Following these transactions, Shulman directly owns 8,509 shares of Rhythm Pharmaceuticals.
In other recent news, Rhythm Pharmaceuticals reported second-quarter 2025 earnings, revealing a wider-than-expected loss per share. The earnings per share (EPS) was -$0.75, missing analyst forecasts of -$0.67, resulting in an 11.94% negative surprise. However, the company’s revenue of $48.5 million exceeded expectations of $43.75 million, marking a significant 29% increase quarter-over-quarter. This strong revenue performance led H.C. Wainwright to raise its price target for Rhythm Pharmaceuticals to $100, maintaining a Buy rating. Similarly, TD Cowen increased its price target to $110, citing the impressive revenue growth that surpassed both consensus and their projections. Citizens JMP also raised its price target to $135, maintaining a Market Outperform rating, and highlighted the company’s ongoing pipeline expansion efforts. Rhythm is progressing with regulatory applications for setmelanotide for hypothalamic obesity in the U.S. and EU this quarter. These developments reflect continued confidence in Rhythm Pharmaceuticals’ growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.